Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects

计划入组 25 人 · 首次发布于 2014 年 12 月 8 日

Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin

计划入组 30 人 · 首次发布于 2024 年 7 月 8 日

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

计划入组 147 人 · 首次发布于 2025 年 8 月 15 日

OBI-866

OBI-833

OBI-898

OBI PHARMA, INC.

China

University of Amsterdam

Netherlands

MediciNova

United States

OBI Pharma and TegMine Therapeutics Form Global License Partnership for Novel Glycan-Targeting ADC

OBI Pharma Initiates Phase 1/2 Trial for Novel TROP2-Targeted ADC OBI-902 in Advanced Solid Tumors

OBI Pharma's Novel TROP2 ADC OBI-902 Receives FDA IND Clearance for Phase 1/2 Trial Using Proprietary GlycOBI® Technology